Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 65

1.

Underutilization and disparities in access to EGFR testing among Medicare patients with lung cancer from 2010 - 2013.

Lynch JA, Berse B, Rabb M, Mosquin P, Chew R, West SL, Coomer N, Becker D, Kautter J.

BMC Cancer. 2018 Mar 20;18(1):306. doi: 10.1186/s12885-018-4190-3.

2.

Improving risk stratification among veterans diagnosed with prostate cancer: impact of the 17-gene prostate score assay.

Lynch JA, Rothney MP, Salup RR, Ercole CE, Mathur SC, Duchene DA, Basler JW, Hernandez J, Liss MA, Porter MP, Wright JL, Risk MC, Garzotto M, Efimova O, Barrett L, Berse B, Kemeter MJ, Febbo PG, Dash A.

Am J Manag Care. 2018 Jan;24(1 Suppl):S4-S10.

3.

Clinical Impact of 21-Gene Recurrence Score Test Within the Veterans Health Administration: Utilization and Receipt of Guideline-Concordant Care.

Hull LE, Lynch JA, Berse BB, DuVall SL, Chun DS, Venne VL, Efimova OV, Icardi MS, Kelley MJ.

Clin Breast Cancer. 2018 Apr;18(2):135-143. doi: 10.1016/j.clbc.2017.11.018. Epub 2017 Nov 29.

PMID:
29306660
4.

In Reference to: "Cost and Utility of Thrombophilia Testing".

Berse B, Lynch JA, Bowen S, Grosse SD.

J Hosp Med. 2017 Sep;12(9):783. doi: 10.12788/jhm.2818. No abstract available.

5.

Clinical decisions surrounding genomic and proteomic testing among United States veterans treated for lung cancer within the Veterans Health Administration.

Efimova O, Berse B, Denhalter DW, DuVall SL, Filipski KK, Icardi M, Kelley MJ, Lynch JA.

BMC Med Inform Decis Mak. 2017 May 30;17(1):71. doi: 10.1186/s12911-017-0475-8.

6.

21-Gene recurrence score testing among Medicare beneficiaries with breast cancer in 2010-2013.

Lynch JA, Berse B, Coomer N, Kautter J.

Genet Med. 2017 Oct;19(10):1134-1143. doi: 10.1038/gim.2017.19. Epub 2017 Mar 23.

PMID:
28333918
7.

Utilization of genetic tests: analysis of gene-specific billing in Medicare claims data.

Lynch JA, Berse B, Dotson WD, Khoury MJ, Coomer N, Kautter J.

Genet Med. 2017 Aug;19(8):890-899. doi: 10.1038/gim.2016.209. Epub 2017 Jan 26.

PMID:
28125086
8.

Epidermal Growth Factor Receptor Mutational Testing and Erlotinib Treatment Among Veterans Diagnosed With Lung Cancer in the United States Department of Veterans Affairs.

Lynch JA, Berse B, Chun D, Rivera D, Filipski KK, Kulich S, Viernes B, DuVall SL, Kelley MJ.

Clin Lung Cancer. 2017 Jul;18(4):401-409. doi: 10.1016/j.cllc.2016.11.018. Epub 2016 Dec 7.

PMID:
28038980
9.

Implementation of Pharmacogenetic Testing Within the Veterans Health Administration From 2011 to 2013.

Lynch J, DuVall SL, Berse B, Whatley A, St Pierre C, Oloruntoba O, Hunt CM.

Mil Med. 2016 Oct;181(10):1375-1381.

PMID:
27753578
10.

BRCA testing within the Department of Veterans Affairs: concordance with clinical practice guidelines.

Chun DS, Berse B, Venne VL, DuVall SL, Filipski KK, Kelley MJ, Meyer LJ, Icardi MS, Lynch JA.

Fam Cancer. 2017 Jan;16(1):41-49. doi: 10.1007/s10689-016-9921-5.

PMID:
27589855
11.

Methods to identify BRCA testing in claims data.

Lynch J, Berse B.

Am J Obstet Gynecol. 2016 Jul;215(1):133-4. doi: 10.1016/j.ajog.2016.03.049. Epub 2016 Apr 12. No abstract available.

PMID:
27083760
12.

Implementation of the 21-gene recurrence score test in the United States in 2011.

Lynch JA, Berse B, Petkov V, Filipski K, Zhou Y, Khoury MJ, Hassett M, Freedman AN.

Genet Med. 2016 Oct;18(10):982-90. doi: 10.1038/gim.2015.218. Epub 2016 Feb 11.

PMID:
26890451
13.

Caring for Patients With Prostate Cancer Who Are BRCA Positive.

Hartzfeld D, Berse B, Lowrance W, Dash A, Brawer M, Lawrence J, Meyer L, Lynch J.

Fed Pract. 2016 Feb;33(Suppl 1):46S-51S.

14.

Molecular diagnostic testing in breast cancer.

Berse B, Lynch JA.

Semin Oncol Nurs. 2015 May;31(2):108-21. doi: 10.1016/j.soncn.2015.02.008. Epub 2015 Feb 26. Review.

PMID:
25951740
15.

Genetic tests to identify risk for breast cancer.

Lynch JA, Venne V, Berse B.

Semin Oncol Nurs. 2015 May;31(2):100-7. doi: 10.1016/j.soncn.2015.02.007. Epub 2015 Feb 26. Review.

16.

Nerve growth factor regulates the expression of the cholinergic locus and the high-affinity choline transporter via the Akt/PKB signaling pathway.

Madziar B, Shah S, Brock M, Burke R, Lopez-Coviella I, Nickel AC, Cakal EB, Blusztajn JK, Berse B.

J Neurochem. 2008 Dec;107(5):1284-93. doi: 10.1111/j.1471-4159.2008.05681.x. Epub 2008 Sep 13.

17.

Differential regulation of the high affinity choline transporter and the cholinergic locus by cAMP signaling pathways.

Brock M, Nickel AC, Madziar B, Blusztajn JK, Berse B.

Brain Res. 2007 May 11;1145:1-10. Epub 2007 Feb 2.

18.

Developmental pattern of expression of BMP receptors and Smads and activation of Smad1 and Smad5 by BMP9 in mouse basal forebrain.

Lopez-Coviella I, Mellott TM, Kovacheva VP, Berse B, Slack BE, Zemelko V, Schnitzler A, Blusztajn JK.

Brain Res. 2006 May 9;1088(1):49-56. Epub 2006 Apr 13.

PMID:
16626664
19.

Expression of high affinity choline transporter during mouse development in vivo and its upregulation by NGF and BMP-4 in vitro.

Berse B, Szczecinska W, Lopez-Coviella I, Madziar B, Zemelko V, Kaminski R, Kozar K, Lips KS, Pfeil U, Blusztajn JK.

Brain Res Dev Brain Res. 2005 Jun 30;157(2):132-40.

PMID:
15885806
20.

Bone morphogenetic protein 9 induces the transcriptome of basal forebrain cholinergic neurons.

Lopez-Coviella I, Follettie MT, Mellott TJ, Kovacheva VP, Slack BE, Diesl V, Berse B, Thies RS, Blusztajn JK.

Proc Natl Acad Sci U S A. 2005 May 10;102(19):6984-9. Epub 2005 May 3.

21.

Regulation of cholinergic gene expression by nerve growth factor depends on the phosphatidylinositol-3'-kinase pathway.

Madziar B, Lopez-Coviella I, Zemelko V, Berse B.

J Neurochem. 2005 Feb;92(4):767-79.

22.

c-ret regulates cholinergic properties in mouse sympathetic neurons: evidence from mutant mice.

Burau K, Stenull I, Huber K, Misawa H, Berse B, Unsicker K, Ernsberger U.

Eur J Neurosci. 2004 Jul;20(2):353-62.

PMID:
15233745
23.

Choline transporter 1 maintains cholinergic function in choline acetyltransferase haploinsufficiency.

Brandon EP, Mellott T, Pizzo DP, Coufal N, D'Amour KA, Gobeske K, Lortie M, López-Coviella I, Berse B, Thal LJ, Gage FH, Blusztajn JK.

J Neurosci. 2004 Jun 16;24(24):5459-66.

24.
25.

Upregulation of acetylcholine synthesis by bone morphogenetic protein 9 in a murine septal cell line.

López-Coviella I, Berse B, Thies RS, Blusztajn JK.

J Physiol Paris. 2002 Jan-Mar;96(1-2):53-9.

PMID:
11755783
26.

Cholinergic differentiation triggered by blocking cell proliferation and treatment with all-trans-retinoic acid.

Malik MA, Greenwood CE, Blusztajn JK, Berse B.

Brain Res. 2000 Aug 25;874(2):178-85.

PMID:
10960602
27.

Induction and maintenance of the neuronal cholinergic phenotype in the central nervous system by BMP-9.

López-Coviella I, Berse B, Krauss R, Thies RS, Blusztajn JK.

Science. 2000 Jul 14;289(5477):313-6.

28.

The cholinergic neuronal phenotype in Alzheimer's disease.

Blusztajn JK, Berse B.

Metab Brain Dis. 2000 Mar;15(1):45-64. Review.

PMID:
10885540
29.

Changes in phospholipase D isoform activity and expression in multidrug-resistant human cancer cells.

Fiucci G, Czarny M, Lavie Y, Zhao D, Berse B, Blusztajn JK, Liscovitch M.

Int J Cancer. 2000 Mar 15;85(6):882-8.

31.
32.

Developmental changes in phospholipase D activity and mRNA levels in rat brain.

Zhao D, Berse B, Holler T, Cermak JM, Blusztajn JK.

Brain Res Dev Brain Res. 1998 Aug 8;109(2):121-7.

PMID:
9729325
33.
34.

Hypoxia regulates the expression of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) and its receptors in human skin.

Detmar M, Brown LF, Berse B, Jackman RW, Elicker BM, Dvorak HF, Claffey KP.

J Invest Dermatol. 1997 Mar;108(3):263-8.

35.

Differences in the developmental expression of the vesicular acetylcholine transporter and choline acetyltransferase in the rat brain.

Holler T, Berse B, Cermak JM, Diebler MF, Blusztajn JK.

Neurosci Lett. 1996 Jul 12;212(2):107-10.

PMID:
8832650
36.

Cytokine and alloantibody networks in long term cardiac allografts in rat recipients treated with rapamycin.

Wasowska B, Wieder KJ, Hancock WW, Zheng XX, Berse B, Binder J, Strom TB, Kupiec-Weglinski JW.

J Immunol. 1996 Jan 1;156(1):395-404.

PMID:
8598490
37.

Balloon catheterization induced arterial expression of embryonic fibronectins.

Dubin D, Peters JH, Brown LF, Logan B, Kent KC, Berse B, Berven S, Cercek B, Sharifi BG, Pratt RE, et al.

Arterioscler Thromb Vasc Biol. 1995 Nov;15(11):1958-67.

PMID:
7583577
39.

Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in cervical neoplasia.

Guidi AJ, Abu-Jawdeh G, Berse B, Jackman RW, Tognazzi K, Dvorak HF, Brown LF.

J Natl Cancer Inst. 1995 Aug 16;87(16):1237-45.

PMID:
7563170
40.
42.

Keratinocyte-derived vascular permeability factor (vascular endothelial growth factor) is a potent mitogen for dermal microvascular endothelial cells.

Detmar M, Yeo KT, Nagy JA, Van de Water L, Brown LF, Berse B, Elicker BM, Ledbetter S, Dvorak HF.

J Invest Dermatol. 1995 Jul;105(1):44-50.

43.

Increased expression of vascular permeability factor (vascular endothelial growth factor) in bullous pemphigoid, dermatitis herpetiformis, and erythema multiforme.

Brown LF, Harrist TJ, Yeo KT, Ståhle-Bäckdahl M, Jackman RW, Berse B, Tognazzi K, Dvorak HF, Detmar M.

J Invest Dermatol. 1995 May;104(5):744-9.

44.

Overexpression of vascular permeability factor (VPF/VEGF) and its endothelial cell receptors in delayed hypersensitivity skin reactions.

Brown LF, Olbricht SM, Berse B, Jackman RW, Matsueda G, Tognazzi KA, Manseau EJ, Dvorak HF, Van de Water L.

J Immunol. 1995 Mar 15;154(6):2801-7.

PMID:
7876550
45.

Biosynthesis of plasma factor XIII: evidence for transcription and translation in hepatoma cells.

Kaczmarek E, Liu Y, Berse B, Chen CS, McDonagh J.

Biochim Biophys Acta. 1995 Feb 22;1247(1):127-34.

PMID:
7873582
46.

Cytokine and alloantibody networks in long-term cardiac allografts in rapamycin-treated sensitized rat recipients.

Wasowska B, Wieder KJ, Hancock WW, Berse B, Binder J, Strom TB, Kupiec-Weglinski JW.

Transplant Proc. 1995 Feb;27(1):423-6. No abstract available.

PMID:
7879047
47.

Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer.

Brown LF, Berse B, Jackman RW, Tognazzi K, Guidi AJ, Dvorak HF, Senger DR, Connolly JL, Schnitt SJ.

Hum Pathol. 1995 Jan;26(1):86-91.

PMID:
7821921
48.

Osteopontin expression and distribution in human carcinomas.

Brown LF, Papadopoulos-Sergiou A, Berse B, Manseau EJ, Tognazzi K, Perruzzi CA, Dvorak HF, Senger DR.

Am J Pathol. 1994 Sep;145(3):610-23.

49.

Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis.

Detmar M, Brown LF, Claffey KP, Yeo KT, Kocher O, Jackman RW, Berse B, Dvorak HF.

J Exp Med. 1994 Sep 1;180(3):1141-6.

50.

Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model.

Miller JW, Adamis AP, Shima DT, D'Amore PA, Moulton RS, O'Reilly MS, Folkman J, Dvorak HF, Brown LF, Berse B, et al.

Am J Pathol. 1994 Sep;145(3):574-84.

Supplemental Content

Support Center